STOCK TITAN

Theratechnologies Inc. Common - THTX STOCK NEWS

Welcome to our dedicated page for Theratechnologies Common news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies Common stock.

Theratechnologies Inc. (symbol: THTX) is a biopharmaceutical company that markets prescription products across the United States, Europe, and Canada. Founded in 1993 and headquartered in Montreal, Canada, the company is dedicated to addressing the unmet medical needs of patients living with HIV and other serious health conditions.

Core Products:

  • EGRIFTA and EGRIFTA SV: These products help reduce excess abdominal fat in HIV-infected patients with lipodystrophy, improving their quality of life.
  • Trogarzo: A vital injection treatment for multidrug-resistant HIV-1 infected patients, offering hope to those who have limited treatment options.

Pipeline Products:

  • F8 Formulation: A promising treatment for HIV-associated lipodystrophy, currently in development.
  • TH-1902: A potential breakthrough in the treatment of triple-negative breast cancer.
  • TH-1904: Targeting ovarian cancer, another pipeline product with significant potential.

Theratechnologies generates significant revenue from its relationship with RxCrossroads, a major customer based in the United States. The company's strategic partnerships and innovative products showcase its commitment to improving patient outcomes in serious medical conditions. With a dedicated focus on research and development, Theratechnologies continues to make strides in the biopharmaceutical industry.

Rhea-AI Summary

Theratechnologies has secured $40 million through its credit agreement with Marathon Asset Management. This funding will assist in purchasing $30 million of convertible notes due in June 2023. The company also has a commitment for a non-dilutive term loan of up to $100 million, available in four tranches. The first tranche has been drawn, which is vital for its operational financing and growth. Investors are urged to consider the risks mentioned in the company’s filings on SEDAR and EDGAR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
none
-
Rhea-AI Summary

Theratechnologies reported a Q2 2022 revenue growth of 8.3% to $19.3 million, while year-to-date revenue climbed by 13.9% to $37.8 million. The company achieved a significant 21.5% increase in EGRIFTA SV® sales. Key developments include the initiation of the TH1902 Basket Trial and a $100 million non-dilutive term loan to strengthen its financial position. The revised FY2022 revenue guidance is set between $79 million and $82 million, reflecting a positive outlook despite operational challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.85%
Tags
-
Rhea-AI Summary

MONTREAL, July 14, 2022 – Theratechnologies (THTX) announced updates on its TH1902 Phase 1 clinical safety study, confirming a favorable safety profile at 300 mg/m2, consistent with previous animal studies. Early efficacy signs were noted in heavily pretreated patients, with confirmed partial responses in prostate cancer cases. Six major cancer centers are now active trial sites. Notably, TH1902's targeted delivery mechanism shows the potential for significantly increased drug accumulation in cancer cells, promising advancements in treating sortilin-expressing tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.85%
Tags
none
Rhea-AI Summary

Theratechnologies (TSX: TH, NASDAQ: THTX) announced a binding commitment for a non-dilutive term loan of up to $100 million from Marathon Asset Management. The initial draw of $40 million will help retire $30 million of convertible notes due in 2023. This financing aims to strengthen the company's balance sheet and extend its cash runway, supporting the advancement of its oncology pipeline and growth of existing products, EGRIFTA SV and Trogarzo. The loan agreement has a five-year term with several tranches available based on performance milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
none
-
Rhea-AI Summary

Theratechnologies has announced a collaborative research project, funded with nearly CAN $2 million, to explore the efficacy and safety of TH1902 for metastatic cancer treatment. The initiative, supported by several organizations including the Quebec Breast Cancer Foundation and MEI, aims to enhance the therapeutic arsenal for patients with hard-to-treat cancers like triple-negative breast cancer. Led by Professor Borhane Annabi at UQAM, this project capitalizes on prior research success and seeks to improve the quality of life for cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Theratechnologies (NASDAQ: THTX) announced it will report its second-quarter financial results for fiscal 2022, ending May 31, on July 14, 2022. The company will host a conference call at 8:30 AM ET the same day, led by President and CEO Paul Lévesque, along with other executives. Participants are encouraged to join early to ensure access. Dial-in details and a webcast link will be provided for the call and replay, which will be available until July 21, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
Rhea-AI Summary

Theratechnologies Inc. (NASDAQ: THTX) appointed Elif McDonald as the new Senior Director of Investor Relations. McDonald brings over 20 years of experience in capital markets and investor relations, particularly in biotech and pharmaceuticals. CEO Paul Lévesque expressed confidence in her ability to enhance investor engagement and raise awareness of the company’s commercial portfolio and research pipeline. This appointment aims to strengthen the company’s visibility and communication strategies in capital markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.65%
Tags
none
-
Rhea-AI Summary

MONTREAL, May 10, 2022 - Theratechnologies (TSX: TH, NASDAQ: THTX) held its annual meeting where shareholders elected Board candidates and appointed KPMG as auditors. Resolutions for a shareholder rights plan and amendments to the share option plan were approved. The company reported successful revenue growth and is building a research pipeline in oncology, aiming for strong returns for shareholders. Chair Dawn Svoronos emphasized the need for a balanced approach between commercial operations and research development for maximizing shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
none
-
Rhea-AI Summary

Theratechnologies announced the initiation of patient enrollment in a basket trial for TH1902, its investigational peptide drug conjugate aimed at treating solid tumors expressing Sortilin. The established dose for this phase 1b study is 300 mg/m2, which is 1.5 times the therapeutic dose of docetaxel, without dose-limiting toxicities observed. The study will assess the efficacy and safety of TH1902 in various cancers including HR+ Breast Cancer and Melanoma. This development follows promising pre-clinical results suggesting TH1902 could significantly enhance docetaxel delivery into cancer cells.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
none
Rhea-AI Summary

Theratechnologies (THTX) has announced it will cease commercialization of Trogarzo® in Europe due to unsatisfactory pricing and reimbursement conditions. The company will focus on the North American market and return European rights to TaiMed Biologics within 180 days. This decision involves restructuring its Dublin subsidiary, resulting in an estimated cash charge of US$1.5 to US$2 million and non-cash charges of about US$6.5 million. European sales, which represented less than 2% of overall revenues, will not impact the company's revenue guidance for fiscal year 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
none

FAQ

What is the current stock price of Theratechnologies Common (THTX)?

The current stock price of Theratechnologies Common (THTX) is $1.79 as of December 20, 2024.

What is the market cap of Theratechnologies Common (THTX)?

The market cap of Theratechnologies Common (THTX) is approximately 74.9M.

What does Theratechnologies Inc. specialize in?

Theratechnologies Inc. specializes in biopharmaceutical solutions for HIV and serious medical conditions like cancer.

Where are Theratechnologies' products marketed?

Theratechnologies markets its products in the United States, Europe, and Canada.

What are the main products offered by Theratechnologies?

The main products include EGRIFTA and EGRIFTA SV for HIV-related lipodystrophy and Trogarzo for multidrug-resistant HIV-1.

What are Theratechnologies' pipeline products?

Pipeline products include the F8 formulation for HIV-associated lipodystrophy, TH-1902 for triple-negative breast cancer, and TH-1904 for ovarian cancer.

When was Theratechnologies Inc. founded?

Theratechnologies Inc. was founded in 1993.

Where is Theratechnologies Inc. headquartered?

Theratechnologies Inc. is headquartered in Montreal, Canada.

Who is a major customer of Theratechnologies?

RxCrossroads, based in the United States, is a major customer of Theratechnologies.

What is the significance of Trogarzo?

Trogarzo is an important treatment for patients with multidrug-resistant HIV-1, providing a crucial option for those with limited alternatives.

How does EGRIFTA benefit HIV patients?

EGRIFTA helps reduce excess abdominal fat in HIV-infected patients with lipodystrophy, improving their health and quality of life.

What is Theratechnologies' approach to innovation?

Theratechnologies focuses on research and development to create innovative treatments for serious medical conditions and improve patient outcomes.

Theratechnologies Inc. Common

Nasdaq:THTX

THTX Rankings

THTX Stock Data

74.95M
28.68M
1.22%
51.56%
0.17%
Biotechnology
Healthcare
Link
United States of America
Montreal